Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries

INTRODUCTION: Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records. METHODS AND ANALYSIS: This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported. ETHICS AND DISSEMINATION: Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences

Chromo- and Fluorogenic Organometallic Sensors

Compounds that change their absorption and/or emission properties in the presence of a target ion or molecule have been studied for many years as the basis for optical sensing. Within this group of compounds, a variety of organometallic complexes have been proposed for the detection of a wide range of analytes such as cations (including H+), anions, gases (e.g. O 2, SO2, organic vapours), small organic molecules, and large biomolecules (e.g. proteins, DNA). This chapter focuses on work reported within the last few years in the area of organometallic sensors. Some of the most extensively studied systems incorporate metal moieties with intense long-lived metal-to-ligand charge transfer (MLCT) excited states as the reporter or indicator unit, such as fac-tricarbonyl Re(I) complexes, cyclometallated Ir(III) species, and diimine Ru(II) or Os(II) derivatives. Other commonly used organometallic sensors are based on Pt-alkynyls and ferrocene fragments. To these reporters, an appropriate recognition or analyte-binding unit is usually attached so that a detectable modification on the colour and/or the emission of the complex occurs upon binding of the analyte. Examples of recognition sites include macrocycles for the binding of cations, H-bonding units selective to specific anions, and DNA intercalating fragments. A different approach is used for the detection of some gases or vapours, where the sensor's response is associated with changes in the crystal packing of the complex on absorption of the gas, or to direct coordination of the analyte to the metal centre

Transgenic animal with monocyte chemotactic protein 1 promoter

[[abstract]]The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1) promoter, wherein the one or more reporter proteins are expressed under the control of the MCP-1 promoter. A method for monitoring endogenous expression of MCP-1 in vivo is also provided, which is useful for identifying a regulator of the expression of MCP-1 or an anti-inflammatory agent

F1B-TMIR plasmid vector and transgenic mouse

[[abstract]]A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described

[[alternative]]Angiogenic evaluation of ginsenoside Rg1 from Panax ginseng in fluorescent transgenic mice

[[abstract]]Background: Evaluation of angiogenesis-inducing compounds is essential in tissue engineering to develop biological substitutes for the repair or regeneration of tissue function. In this report, we evaluated the angiogenic ability of ginsenoside Rg(1) from Panax ginseng, in Matrigel implanted on fluorescent transgenic mice. Methods: The in vitro proliferation ability of each test agent was estimated by MTS assay. The Matrigel loaded with basic fibroblast growth factor (bFGF) or Rg(1) and Matrigel alone were implanted on fluorescent transgenic mice and were retrieved at 1, 4, 6 and 8 weeks after implantation to measure various conventional markers for angiogenesis including neo-vascular density and hemoglobin content. Additionally, the functional neo-vasculature in the implanted Matrigel was visualized using confocal laser scanning microscopy (CLSM). Results: The in vitro results indicated that the stimulating effect of Rg(1) on HUVECs proliferation remained unchanged after dissolved for 30 days in culture medium at 37 degrees C when compared with the effect of bFGF. One week after implantation in transgenic mice, bFGF or Rg(1) mixed in Matrigel plug significantly enhanced angiogenesis; however, at 6 weeks a significant decrease in angiogenic effect was observed in Matrigel with bFGF, but not in Matrigel with Rg(1). The neo-vessels structure was visualized in three dimensions (3D) by CLSM and the results were in agreement with other conventional measurements for angiogenesis. Conclusion: These findings confirm that Rg(1) could be used in tissue tissue-engineering applications and that the fluorescent transgenic mice can be a useful experimental model for studying angiogenesis

[[alternative]]Transgenic animal with monocyte chemotactic protein 1 promoter

[[abstract]]本發明係關於一種轉殖基因動物，其在基因組中包含編碼一或多種報導蛋白之聚核苷酸，以及單核細胞趨化蛋白-1(MCP-1)啟動子，其中該一或多種報導蛋白是在該MCP-1啟動子之控制下表現。本發明亦提供一種用於在體內監測MCP-1之內源性表現的方法，其可用於辨識MCP-1表現之調控劑或抗發炎劑。The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1) promoter, wherein the one or more reporter proteins are expressed under the control of the MCP-1 promoter. A method for monitoring endogenous expression of MCP-1in vivo is also provided, which is useful for identifying a regulator of the expression of MCP-1 or an anti-inflammatory agent

Plasma Enhanced Biocompatible and Photocatalytic Antibacterial Degradable Magnesium Alloy for Bone Facture Fixation

Poster presentation - PS1 Biomaterials — Bone: Poster No. 39

Improving corrosion resistance and biocompatibility of WE43 magnesium alloy by custom made dual plasma implantation

Conference Theme: Biomaterials Interfaces and NanobiomaterialsConcurrent 2: Materials for regenerative medicine